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A B S T R A C T   
The latest pandemic, coronavirus disease-2019 (COVID-19), is associated with high prevalence and easy trans-
mission, which is expanding globally with no conventional treatment or vaccine. The new virus revealed 79% 
and 50% genomic similarities with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East 
respiratory syndrome coronavirus (MERS-CoV), respectively. Accordingly, since the disease resists testing and 
adopting new therapeutics, repositioning pre-existing drugs may present a fast and attractive strategy with 
known safety, characteristics, and dosage used. However, they are not specific and targeted. Therefore, several 
drugs have been investigated for their efficacy and safety in the treatment of COVID-19; most of them are un-
dergoing clinical trials. This article summarizes clinical investigations of potential therapeutic drugs used as 
COVID-19 therapy. Subsequently, it prepares a pattern of results and therapeutic targets to help further exper-
iment designs. We have investigated drugs as classified in the following three groups; 1) The drugs which 
computationally showed effectiveness (in silico) but needed further lab confirmations; 2) Emetine, Teicoplanin, 
and Nelfinavir have shown effectiveness in vitro; 3) The drugs currently under clinical trial.   
1. Introduction 
In late December 2019, novel pneumonia began in Wuhan, China, 
and has since spread worldwide, being established as the global 
pandemic health emergency. The causative pathogen has been intro-
duced as the 2019 novel coronavirus (2019-nCoV) described by the 
International Committee on Taxonomy of Viruses as the severe acute 
respiratory syndrome coronavirus-2 (SARS-CoV-2). On 11 February 
2020, the disease was announced coronavirus disease-2019 (COVID- 
2019) by the World Health Organization (WHO) (Hassan et al., 2020; Lai 
et al., 2020). 
SARS-CoV-2 is a member of an enveloped single-strand RNA virus 
family named coronaviruses, which belong to the Coronaviridae family 
of the order Nidovirales. There are four genera in this subfamily: Alpha, 
Beta, Delta, and Gamma-Coronaviruses (CoVs) that cause mild to severe 
lower respiratory tract disease (Ko et al., 2020). Since the beginning of 
the 21st century, outbreaks of fatal human pneumonia have occurred via 
CoVs, such as severe acute respiratory syndrome coronavirus (SAR-
S-CoV) and the Middle East Respiratory Syndrome Coronavirus (MER-
S-CoV). SARS-CoV spread to five countries in 2003 after its emergence in 
Guangdong province of China, infecting 8098 people and leaving 774 
deaths. MERS-CoV appeared in Arabian Peninsula in 2012, was isolated 
in 27 countries, and infected 2494 people with 858 related deaths. The 
fatality rate was 10% and 35% for SARS-CoV and MERS-CoV, respec-
tively (Wu et al., 2020a), belonging to the genus Beta-CoV. Of note, 
sequencing studies have identified SARS-CoV-2 as a new member of 
Beta-CoVs with 80% similarities, which have the most extended 
genome, containing 27 to 37 thousand bases among RNA viruses (Payne, 
2017). 
Coronaviruses generally have four structural proteins: Spike (S), 
envelope (E), membrane (M), and nucleocapsid (N) (Wu et al., 2020a). 
Notably, the virus can enter the host cell through the S protein. It is 
cleaved by the host protease into two functional subunits, S1 and S2, 
which are in charge of the host cell binding and the viral-cellular 
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membrane fusion, respectively. Different CoVs recognize a variety of 
proteases and entry receptors, where SARS-CoV and SARS-CoV-2 pro-
cess their S protein via employing the cellular serine protease TMPRSS2 
and subsequent interaction with angiotensin-converting enzyme two 
cellular (ACE2) receptors (Hoffmann et al., 2020a; Walls et al., 2020; 
Wang et al., 2020c). These viral components can be targeted as potential 
sites for drug therapy against COVID-19 (Fig. 1). However, the 
pathophysiology for SARS-CoV-2 has not been well spotted, but similar 
to SARS-CoV, viral replication leads to aggressive inflammation and 
causes acute lung injury. After that, the leading cause of SARS-CoV-2 
fatality is uncontrolled pulmonary inflammation (Fu et al., 2020). 
Remarkably, COVID-19 is clinically manifested as fever accompanied by 
chills or headache, fatigue, myalgia, shortness of breath, and dry 
coughing. Gastrointestinal disorders and lymphopenia have also been 
Fig. 1. The infection cycle of SARS-COV-2 and the effecting pints of potential drugs against COVID-19.1) SARS-COV-2 binds to the cell surface through ACE-II and 
TMPRSS2 cell membrane proteins (Entrance blocking drugs). 2) Virus enters to the cells through receptor mediated endocytosis and formation of endosomes, 3) 
Fusion of virus to endosomes leads to the genome releasing to the cytoplasm (Endosome fusion blocking agents), 4) Replication of the genome (Replication in-
hibitors), 5) Transcription of viral genes, 6) Translation of virus proteins (Virus proteins inhibitors), 7) Packaging the virus particles and, 8) releasing the newly 
formed virus particles to the extracellular environment. Cytokine storm and inflammatory mediators in the infection site leads to tissue damage (Inhibitors of in-
flammatory mediators). Clot formation, as a secondary effect of COVID-19, is inhibited by heparins. Bradykinin receptor repressor inhibits plasma leakage to the lung 
tissue. BK: Bradykinin, ACE-II angiotensin converting enzyme 2, IFN: Interferon, IL-6: Interleukin 6, IL-1, Interleukin 1, TNFa: Tumor necrosis factor α, EGFR: Epidermal 
growth factor receptor, TMPRSS2: Transmembrane serine protease 2. 
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reported in severe cases. Besides, lung imaging shows viral lung 
involvement even in asymptomatic individuals (Huang et al., 2020a; Liu 
et al., 2020b). 
There has been a wide prevalence of this infectious disease, with 
15,961,099 cases and 643,118 related deaths as of 25 July 2020, and 
there is still no specific medication for it. In this regard, the most 
convenient way to develop medicines is to use pre-existing and mar-
keted drugs whose mechanisms, characteristics, potential efficacy, 
cytotoxicity, and dosages have been approved. However, being too 
broad-spectrum, these therapies cannot kill CoVs specifically (Ko et al., 
2020; Wu et al., 2020a). 
In this review, we studied the clinical trials published on the treat-
ment of COVID-19 and summarized recent clinical experiences and 
treatment outcomes to provide a view of potentially useful drugs. 
2. Antiviral drugs 
2.1. Darunavir 
Darunavir is a nonpeptidyl HIV-1 protease inhibitor with a bimodal 
mechanism of action including, inhibition of HIV protease dimerization 
and protease enzymatic activity. It selectively inhibits Gag-Pol poly-
protein cleavage leading to immature and non-infectious viral particles 
(Spagnuolo et al., 2018; Aok et al., 2018). One of the best targets for 
SARS-COV-2 is its main protease, so its inhibition may block the virus. 
Several in silico studies have introduced Darunavir with a high score for 
binding to SARS-COV-2 protease, which may be useful in the battle with 
the COVID-19 disease after further testing (Beck et al., 2020; Khan et al., 
2020; Pant et al., 2020). 
Although Darunavir was thought to be an effective candidate, De 
Meyer et al. showed this drug does not have an antiviral effect for 
treatment of covid-19. (De Meyer et al., 2020). 
Reportedly, Darunavir’s co-administration with other antivirals has 
had positive effects on SARS-CoV-2 patients (Costanzo et al., 2020; 
Spezzani et al., 2020). Darunavir has also been used for a married couple 
in which the wife was partially immunocompromised because of starting 
chemotherapy. They received 200 mg Darunavir/Cobicistat and 
Hydroxychloroquine along with antiviral therapy, twice daily. Both 
patients were recovered (Spezzani et al., 2020). There is a report of HIV 
positive patients who received Darunavir-based antiretroviral treatment 
(800 mg), which were also admitted as SARS-CoV-2 positive. This study 
suggests that despite Darunavir’s potential effectiveness, it did not 
protect people living with HIV from SARS-CoV-2 infection, at least 800 
mg, the currently given dosage (Riva et al., 2020). 
2.2. Oseltamivir 
Oseltamivir is an antiviral drug that inhibits Neuraminidase. It 
blocks the activity of various types of influenza A and B viruses. Neur-
aminidase enzyme, expressed on the viral surface, plays an essential role 
in viral entry to host cells, viral release from infected cells, and further 
spread in the body. Oseltamivir, as the Neuraminidase inhibitor, pre-
vents the release of virions, keeps them attached to the membrane of 
previously infected cells and subsequently hinders their expansion in the 
body (Gubareva et al., 2000; Ward et al., 2005). A report from Rajavithi 
Hospital in Bangkok, prescribing Oseltamivir, in combination with 
Lopinavir/Ritonavir, alleviated several patients’ symptoms (Offord, 
2020). Subsequently, a group has explored the synergistic effects of 
these three drugs in silico, and they suggested that their combination is 
highly effective against SARS-CoV-2 protease (Muralidharan et al., 
2020). However, case report studies using 75 mg twice a day have 
suggested that Oseltamivir is ineffective against COVID-19, possibly 
because the SARS-COV-2 virus lacks Neuraminidase (Li et al., 2020b; 
Rosa and Santos, 2020; Wang et al., 2020a). Recently, through in-silico 
and in-vitro study and clinical case analysis, some researchers demon-
strated that Oseltamivir is not useful for patients suffering from covid-19 
(Qi et al., 2020). 
2.3. Umifenovir 
Umifenovir is a broad-spectrum antiviral compound, licensed as an 
anti-influenza drug. This antiviral agent was developed at the Russian 
Research Chemical and Pharmaceutical Institute about 25 years ago to 
treat influenza A and B in Russia and China. It is also patented for its 
medicinal use against SARS-CoV since 2004 (Blaising et al., 2014). Viral 
glycoproteins, responsible for fusion and cellular recognition, are 
affected by Umifenovir, which interacts with their aromatic residues. 
Subsequently, Umifenovir interferes with clathrin-mediated exocytosis 
through the plasma membrane interaction or directly intercalate into 
membrane lipids, specifically through hemagglutinin inhibition (HA) 
(Polyak et al., 2019; Kadam et al., 2017; Blaising et al., 2013). 
It was observed that Umifenovir binds directly to influenza HA and 
increases its stability blocking its transition to the functional form. As a 
result, the viral-host fusion is inhibited, and the host cell entry is blocked 
(Haviernik et al., 2018; Hulseberg et al., 2019). Meanwhile, it has an 
immune-stimulating effect with interferons’ induction, enhancement of 
phagocytosis, and activation of natural killer cells. Fortunately, reports 
have revealed a favorable safety profile (Li et al., 2020c). Due to such 
broad antiviral activities, Umifenovir has been proposed as a potential 
treatment for COVID-19. In a clinical study on 50 cases at ELACOI 
hospital, Umifenovir monotherapy at the dose of 100 mg did not 
significantly improve patients compared to control (Li et al., 2020c). In 
another study in non- Intensive Care Unit (ICU) patients who received 
Umifenovir, compared to control, no improvement in outcome was 
observed (Lian et al., 2020). The other group compared the Favipiravir 
and Umifenovir on 120 cases in each group. The clinical recovery rate 
was 51.67% and 61.21% for Umifenovir and Favipiravir group, 
respectively (Chen et al., 2020a). 
2.4. Favipiravir 
Favipiravir, an anti-RNA virus drug, has been introduced in Japan for 
novel or re-emerging influenza viruses in 2014. It undergoes ribosyla-
tion and phosphorylation intracellularly to become activated and in-
corporates into the virus RNA through substitution with purine 
nucleosides. Subsequently, the RNA dependent RNA polymerase (RdRp) 
of viruses will be inhibited and prevented RNA strand elongation and 
viral proliferation. In addition to influenza, Favipiravir works against a 
broad range of RNA viruses, including Rhinovirus, Arenavirus, Bunya-
virus, Flavivirus, and filoviruses, causing hemorrhagic fever as well as 
the Ebola virus. Noticeably, the RNA structure of SARS-CoV-2 and its 
similarities to SARS-CoV makes Favipiravir a potential candidate for 
COVID-19 treatment (Du and Chen, 2020; Shiraki and Daikoku, 2020). 
Consequently, a clinical trial was conducted in Shenzhen, with 80 
patients recruited. The results demonstrated that viral clearance time 
became significantly shorter, and chest X-ray imaging improved at a 
higher rate in the Favipiravir group (91.43% and 62%, respectively) (Cai 
et al., 2020). Another study on 120 patients confirmed Favipiravir’s 
efficacy with a 7-day clinical recovery rate of 71.43% and reduction of 
fever and cough (Chen et al., 2020a). Based on a systematic review and 
meta-analysis by Shrestha et al., the use of Favipiravir improves clinical 
symptoms (Shrestha et al., 2020). Another systematic review study 
demonstrated that Favipiravir has faster viral clearance than Lopina-
vir/Ritonavir and Umifenovir (Siordia et al., 2020). 
2.5. Remdesivir 
Remdesivir is a small-molecule monophosphoramidate prodrug. It is 
an adenosine analog that blocks the RNA-dependent RNA-polymerase 
through its nucleoside component. It works after the virus entry into the 
host cell. After entering the cells, Remdesivir is cleaved to the nucleoside 
monophosphate analog and subsequently goes into further 
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phosphorylation to yield its active triphosphate form (RDV-TP), which 
resembles Adenosine triphosphate (ATP). Competing with ATP, RDV-TP 
incorporates by the RdRp and viral RNA chain complex leading to pre- 
mature termination of viral RNA transcription and subsequent RNA 
synthesis inhibition (Khanal et al., 2020; Saha et al., 2020). 
Gilead Science synthesized this medication in 2017 for Ebola virus 
infection treatment, and further studies considered it a right candidate 
against coronaviruses. In vitro and in vivo experiments on SARS-CoV 
and MERS-CoV showed that Remdesivir could inhibit the viruses’ 
replication and reduces viral lung load and SARS-CoV-induced lung 
pathology such as denuding bronchiolitis (Al-Tawfiq et al., 2020; Ko 
et al., 2020). Therefore, on the outbreak of SARS-CoV-2, a study using 
molecular dynamic simulation examined the inhibitory effect of 
Remdesivir on RNA-dependent RNA polymerase of SARS-CoV-2. They 
reported that the relative free energy of Remdesivir is − 8.28 ± 0.65 
kcal/mol, which is too strong compared to the natural substrate ATP 
(− 4.14 ± 0.89 kcal/mol) (Zhang and Zhou, 2020). Thus, further ex-
periments were designed on Vero E6 cells (a lineage of kidney epithelial) 
for in vitro examinations. One study working on Remdesivir and Chlo-
roquine suggested the half-maximal effective concentration (EC50) and 
the half-cytotoxic concentration (CC50) values of Remdesivir as 0.77 μM 
and 100 μM, respectively, confirming its inhibition activity (Wang et al., 
2020b). Another experiment carried out on the same cell line estimated 
its EC50 at 23.15 μM (Choy et al., 2020). Specifically, a human study 
was designed on patients hospitalized with confirmed COVID-19. Fif-
ty-three patients, including the study, received 200 mg of Remdesivir 
intravenously on day 1, followed by 100 mg daily for nine days. A total 
of 47% of patients were discharged, 68% improved significantly, and 
13% died. The most common adverse events were diarrhea, rash, renal 
impairment, hypotension, and increased hepatic enzymes (Grein et al., 
2020). There is a report on a COVID-19 patient that is declaring the 
delayed effectiveness of Remdesivir. The drug was administered 13 days 
after the onset of symptoms. Sixty hours after initiating Remdesivir, the 
patient was extubated and continued the recovery into a stable condition 
(Hillaker et al., 2020). 
Moreover, a double-blind trial was carried out on 453 patients in the 
two groups of Remdesivir and placebo, designed for 28 days. The 
loading dose of Remdisivir is considered 200 mg in 350 ml normal saline 
infused intravenously over approximately 30–60 min for the first day 
and 100 mg in 250 ml normal saline for nine days. Serious consider-
ations have been assumed for this study (Cao et al., 2020a). However, in 
a clinical trial in China, the use of Remdesivir for severe covid-19 pa-
tients did not show remarkable advantages (Wang et al., 2020). 
On May 1, 2020, the FDA provided an Emergency Use Authorization 
(EUA) for Remdesivir as the treatment of hospitalized COVID-19 pa-
tients (Rhoades, 2020). Recently it was noted that for the mild or 
moderate covid-19 patients, Remdesivir is not recommended. Still, for 
the ones who require respiratory support, the use of Remdesivir de-
creases the improvement time and reduces the hazard of progression 
(Young et al., 2020). 
Remdesivir is the only medication that has been approved for 
COVID-19 infection by the U.S. Food and Drug Administration so far. 
2.6. Ribavirin 
As a guanosine analog, Ribavirin prevents RNA and DNA virus’s 
replication and inhibits RNA capping, leading to RNA degradation. It 
also inhibits inosine monophosphate dehydrogenase, which results in 
the prevention of natural guanosine generation. In general, Ribavirin 
acts in several mechanisms of action. Ribavirin triphosphate, one of its 
predominant metabolites, binds to the nucleotide-binding site of mRNA 
polymerase enzyme instead of correct nucleotide, resulting in defective 
production virions and viral replication reduction. It can also incorpo-
rate at the 5՛-end of viral mRNA and disrupt the posttranslational 
capping. The next target of Ribavirin is inosine monophosphate dehy-
drogenase (IMPDH), which provides the intracellular guanosine 
triphosphate (GTP). Ribavirin mimics the endogenous substrate of 
IMPDH, inosine-5-monophosphate, occupying the substrate-binding site 
leading to the depletion of GTP pools and subsequent viral limitation 
genome replication. Furthermore, it acts as a mutagen in some viruses, 
causing an error catastrophe. In this regard, Ribavirin triphosphate is 
substituted for GTP and pairs with cytidine triphosphate or uridine 
triphosphate through which can block the RNA elongation and produce 
defective virions (Khalili et al., 2020; Nyström et al., 2019; Patterson 
et al., 1990; Song et al., 2020; Te et al., 2007). 
Ribavirin has been active as an antiviral agent against the respiratory 
syncytial virus (RSV), SARS-CoV, and MERS-CoV. Now in the outbreak 
of COVID-19, virtual analysis has suggested it as a potential treatment 
(Elfiky, 2020). In an in vitro study on Vero E6 cells infected by 
COVID-19, Ribavirin has confirmed antiviral activity. They reported its 
EC50 as 109.50 μM and CC50 > 400 μM (Wang et al., 2020b). Although 
no definitive clinical study has yet registered the benefits of Ribavirin on 
COVID-19, there is a study that has worked on 3 Chines hospital, where 
Ribavirin was prescribed intravenously for 3–12 days along with other 
drugs. There was no death among the 80 cases, 21 patients (23.75%) had 
an average length of hospital stay of 8 days, and others were still in 
hospital after 12 days (Wu et al., 2020b). Also, a retrospective cohort 
study reported that Ribavirin could not decrease the mortality rate; 
16/1% of patients with severe coronavirus disease treated by Ribavirin 
died compared to 24.6% in the control group (Tong et al., 2020). 
However, most of the previous studies on SARS CoV and MERS CoV 
suggest Ribavirin as an add-on therapy, which is also indicated by 
China’s NHC for COVID-19 in combination with Lopinavir/Ritonavir or 
interferon, reportedly (Song et al., 2020). 
2.7. Nafamostat and Camostat 
Nafamostat mesylate and Camostat mesylate belong to synthetic 
serine protease inhibitors; Nafamostat mesylate, also named FUT-175 
and 6′-amidino-2-naphthyl-4 -guanidinobenzoate dihydrochloride. At 
the first phase of infection with SARS-CoV-2 Virus, Nafamostat can 
inhibit the S-mediated membrane fusion. This drug is used for acute 
pancreatitis, and intracellular coagulation has been revealed to be useful 
in the first phase of infection with the SARS-CoV-2 virus. Nafamostat 
prevents cell entry of virus by inhibiting enzyme transmembrane pro-
tease serine 2 (TMPRSS2), blocking the S-protein mediated membrane 
fusion. These inhibitors form a close interaction to Asp435 in the S1 
pocket and close contact with catalytic serine in TMPRSS2 and produce 
a reactive complex, resulting in enzyme hampering (Hempel et al., 2020; 
Hoffmann et al., 2020b). 
A German group introduced Nafamostat as an inhibitor of SARS-CoV- 
2 infection. They stated that Nafmostat is more effective than Camostat 
to prevent membrane fusion and host cell entry (Hoffmann et al., 
2020b). In a comparative analysis, covid-19 antiviral drugs’ efficacy was 
determined in human lung cells and revealed Nafamostat is the most 
potent drug for blocking virus entry (Ko et al., 2020). Moreover, a case 
report on three old patients with COVID-19 pneumonia showed that 
Nafamostat’s use could improve clinical symptoms. Disseminated 
intravascular coagulation (DIC) dose (0.06–0.2 mg/kg/hour) was used 
for these patients (Jang and Rhee, 2020). However, harmful incidents 
such as bleeding should be considered after using this drug (Hifumi 
et al., 2020). 
2.8. Lopinavir/Ritonavir 
Lopinavir is a protease inhibitor approved against the human im-
munodeficiency virus 1 (HIV-1), which is usually administered in 
combination with Ritonavir. Ritonavir, a cytochrome P450 3A inhibitor, 
increases the plasma half-life of Lopinavir. These protease inhibitors 
mimic the normal peptide linkage and bind to the substrate-binding 
pockets of viral enzymes such as papain-like cysteine proteinase 
(PLpro) and 3C-like proteinase (3CLpro). By inhibiting the enzyme 
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activity, drugs prevent the proteolysis of Gag polyprotein precursors, 
which causes the formation of immature, non-infectious viral particles 
(Uzunova et al., 2020). 
Previous in vitro studies and trials on coronaviruses (SARS and 
MERS) have reported that Lopinavir/Ritonavir conferred clinical bene-
fits, either in single administrations or combined with other agents as 
ribavirin, corticosteroids, etc. (Li et al., 2020c; Song et al., 2020; Yao 
et al., 2020a). They could lower the viral load, mortality rates, and 
adverse respiratory distress syndrome (ARDS). Of note, the in vitro EC50 
of Lopinavir ranged from 4.0 to 10.7 μg/ml for SARS-CoV to 5.0–7.0 
μg/ml for MERS-CoV (Cao et al., 2020b). There is a report on a patient in 
Korea prescribed to use Lopinavir/Ritonavir (200 mg/50 mg) on day 10 
of the contraction. They observed a decrease in the viral load since then 
(Lim et al., 2020). besides, a group of researchers conducted a trial on 
199 COVID-19 patients in two groups; 1- Lopinavir/Ritonavir along with 
standard care and 2- standard-care alone (Comprising supplemental 
oxygen, ventilation, antibiotic therapy, and vasopressor support, if 
necessary). Patients received 400 mg Lopinavir and 100 mg Ritonavir 
two times a day for up to 14 days. Approximately 45% and 40% of the 
patients were detected with positive viral RNA on day 14 and 28, 
respectively. Indeed, treatment with Lopinavir/Ritonavir had no benefit 
beyond standard care. Furthermore, the treated group encountered 
commonly gastrointestinal adverse events, including nausea, vomiting, 
and diarrhea, although the overall reported adverse events were 48.4% 
in the Lopinavir/Ritonavir group and 49.5% in the standard care group 
(Cao et al., 2020b). Another study enrolled 86 patients in 3 groups: i) 34 
patients receiving Lopinavir/Ritonavir (200 mg/50 mg) twice daily ii) 
35 patients receiving Umifenovir (100 mg) three times daily iii) 17 pa-
tients with no antiviral. 
Repeatedly, groups didn’t acquire significant differences in 
improvement rates (Li et al., 2020c). Despite the lack of statistically 
significant difference, the lopinavir-ritonavir group had a numerical 
decrease in mortality rate, and less stayed in an intensive care unit. 
Based on these findings, some researchers suggested the earlier usage of 
Lopinavir/Ritonavir in the course of the disease (Owa et al., 2020). 
2.9. Nelfinavir 
Nelfinavir is a viral protease inhibitor, approved as an HIV-1 prote-
ase inhibitor by the FDA in 1997. HIV protease activity is essential for 
the cleavage of viral polyproteins leading to subsequent assembly of 
immature virus proteins into infectious virions. Nelfinavir prevents 
proteolytic cleavage of viral polyproteins by occupying the enzyme 
active site— results in the formation of un-developed non-infectious 
viral particles. Moreover, the main protease or chymotrypsin-like pro-
tease of COVID-19 has been suggested as a potential drug target (Kaldor 
et al., 1997; Xu et al., 2020b; Yamamoto et al., 2004). In silico studies 
modeling the main protease of SARS-CoV-2 have introduced Nelfinavir 
as the best candidate with the most binding free energy (Xu et al., 
2020b). 
Furthermore, studies on SARS-CoV have revealed that Nelfinavir has 
strongly inhibited SARS-CoV replication, lowering viral antigens 
significantly. Nelfinavir is also very safe, with mild diarrhea as a side 
effect in 15–20% of patients (Yamamoto et al., 2004). Therefore, an in 
vitro study evaluated its efficacy on SARS-CoV-2. The findings revealed 
that Nelfinavir could effectively inhibit SARS-CoC-2 replication in vitro. 
This study suggested Nelfinavir concentration of 1.13 μM and 1.76 μM as 
the sufficient concentrations for 50% and 90% inhibition (EC50 and 
EC90), respectively (Yamamoto et al., 2020). The results suggest that 
Nelfinavair can be clinically assessed. Researchers showed that Nelfi-
navir is a potent inhibitor of cell membrane fusion resulting from 
covid-19 spike glycoprotein based on an in-vitro study. So they sug-
gested subsequent and more evaluation of the potential of Nelfinavir to 
prevent virus spread when the first symptoms of SARS-CoV-2 appear in 
patients (Musarrat et al., 2020). 
3. Antibacterials 
3.1. Teicoplanin 
Teicoplanin, a glycopeptide antibiotic, is currently applied as a 
therapy for gram-positive bacterial infections such as Methicillin- 
resistant Staphylococcus aureus, septicemia, endocarditis, and lower 
respiratory tract infections. It has already shown benefits against various 
viruses, including Ebola, influenza virus, flavivirus, hepatitis C virus, 
HIV, MERS-CoV, and SARS-CoV (Baron et al., 2020; Brogden and Peters, 
1994). 
Teicoplanin, a glycopeptide antibiotic, blocks the cathepsin L, 
located in the late endosome. Cathepsin L mediates the cleavages of viral 
S protein, which leads to the virus-host cell fusion and viral genome 
released into the cytoplasm. Therefore, blocking this mechanism would 
prevent the viral replication cycle (Jean et al., 2020; Zhang et al., 
2020b). Reportedly, the cathepsin L cleavage site is conserved among 
coronaviruses, SARS-CoV, and SARS-CoV-2. In an in vitro study on 
SARS-CoV-2, Teicoplanin could prevent viruses’ entrance into the 
cytoplasm. They determined its half-maximal inhibitory concentration 
(IC50) as 1.66 μM (Zhang et al., 2020b). Recently in Italy, a cohort study 
on 21 COVID-19 patients hospitalized in ICU received Teicoplanin 6 
mg/kg every 24 h for 7–12 days. The findings showed a viral clearance 
rate of 40% and suggested that Teicoplanin might be potentially 
appropriate for the treatment of SARS-Cov-2 infection (Ceccarelli et al., 
2020). 
3.2. Azithromycin 
Azithromycin, a macrolide antimicrobial agent, acts against a broad 
range of Gram-positive and Gram-negative bacteria and plays an 
immunomodulator. Azithromycin targets bacterial 50s ribosomal sub-
unit through binding to its 23s rRNA, leading to the inhibition of its 
assembly, which results in bacterial protein synthesis blockade. Pre-
vention of the transpeptidation/translocation step of protein synthesis, 
Azithromycin controls various bacterial infections (Champney et al., 
2002; Parnham et al., 2014). It has anti-inflammatory and direct anti-
viral effects. Previous in vitro reports suggested it combined with 
Hydroxychloroquine as an active agent against Zika and Ebola viruses. 
Azithromycin is a common therapy for many chronic lung diseases, 
including chronic obstructive pulmonary disease (COPD), asthma, 
interstitial lung diseases, bronchiectasis, and cystic fibrosis (La Scola 
et al.; Martinez et al., 2008). Thus, in studies, it has been suggested as 
the right candidate for co-treatment with Hydroxychloroquine for 
COVID-19. In an in vitro study on Vero E6 cells, the concentration of 1, 
2, and 5 μM of Hydroxychloroquine and 2, 5, and 10 μM for Azi-
thromycin were used. They observed viral replication inhibition for 5 
μM of Hydroxychloroquine in combination with Azithromycin at 10 and 
5 μM (Andreani et al., 2020). Another study, following 80 patients for at 
least six days, suggested 200 mg of oral Hydroxychloroquine sulfate, 
three times per day combined with 500 mg of Azithromycin on the first 
day, then 250 mg daily for the following four days. The viral RNA load 
was decreased rapidly. All the combinational group participants were 
virologically cured on day 6. The majority of patients, 81.3%, were 
favorably discharged from their unit, and only 15% required oxygen 
therapy (Gautret et al., 2020b). There is also an open-label non--
randomized clinical trial conducted on 36 patients. All patients were 
treated with oral Hydroxychloroquine sulfate 200 mg, three times per 
day, while six patients received Azithromycin (500 mg on day one fol-
lowed by 250 mg per day). 100% of patients treated with Hydroxy-
chloroquine and Azithromycin were cured virologically compared with 
single-drug therapy. In comparison, 57.1% of patients received single 
Hydroxychloroquine and 12.5% in the control group (Gautret et al., 
2020a). 
However, there is a preliminary work on QT interval (electrical 
disturbance of the cardiovascular system, seen on an electrocardiogram) 
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of this combination therapy. They reported the changes in the QT in-
terval of 84 adult patients, of which 11% demonstrated an increased risk 
of malignant arrhythmia and sudden cardiac death (Chorin et al., 2020). 
In this regard, they suggest there should be vital considerations to pre-
scribe this compound. Further, in a randomized clinical trial in Brazil, 
447 patients with severe covid-19 received Azithromycin (500 mg for 
ten days) in addition to standard of care, including Hydroxychloroquine 
or standard of care alone. The findings revealed Azithromycin has no 
beneficial effect on clinical outcome (Furtado et al., 2020; Oldenburg 
et al., 2020). 
4. Antimalarial agents 
4.1. Chloroquine & hydroxychloroquine 
Chloroquine and Hydroxychloroquine are antimalarial drugs that 
inhibit lysosomes’ vital functions by increasing pH, which results in 
blocking endosome-mediated entry (Al-Bari, 2017). They can also 
interfere with nucleic acid replication, viral protein glycosylation, virus 
assembly, and release. Notably, Chloroquine has an 
immune-modulatory activity, which may enhance its antiviral effects 
synergistically (Ponticelli and Moroni, 2017). However, its utilization is 
restricted because of its potential overdose, acute poisoning, and death. 
Hydroxychloroquine is a derivative of Chloroquine, which has been 
demonstrated to be much less toxic (4̴0%) (Liu et al., 2020a). It is known 
for its clinical safety profile. Meanwhile, both effectively treat many 
inflammatory diseases such as rheumatoid arthritis and lupus by 
inhibiting cytokine (IL-1 and IL-6) generation, phospholipase A2 and 
matrix metalloproteinases, and modulating B and T cell function (Singh 
et al., 2020). However, they can cause some side effects, such as 
gastrointestinal disorders, headaches, retinopathy, and arrhythmia. 
In an in vitro study on SARS-CoV, Chloroquine was introduced as a 
potent prophylactic and therapeutic treatment that interferes with the 
glycosylation of viral cellular receptors (Vincent et al., 2005). By the 
outbreak of SARS-CoV2, a team examining Chloroquine on Vero E6 cells 
indicated that it could potently block virus infection with an EC90 value 
of 6.90 μM (Wang et al., 2020b). Besides, another in vitro study was 
designed to compare the antiviral effects of Hydroxychloroquine and 
Chloroquine. The 50% cytotoxic concentration (CC50) values were 
evaluated as 273.20 and 249.50 μM for Chloroquine and Hydroxy-
chloroquine, respectively. The total data suggested that although 
Hydroxychloroquine can efficiently inhibit SARS-CoV-2, its 
anti-SARS-CoV-2 activity is less potent than Chloroquine (Liu et al., 
2020a). In contrast, Dongyang Liu and his colleagues found Hydroxy-
chloroquine more potent than Chloroquine based on their half-maximal 
effective concentration (EC50), evaluated as 0.72 μM and 5.47 μM for 
Hydroxychloroquine and Chloroquine, respectively (Yao et al., 2020b). 
An open-label non-randomized clinical trial targeted 36 COVID-19 
patients and prescribed 600 mg/day Hydroxychloroquine for six days. 
Seventy percent of patients were virologically cured compared with 
12.5% in the control group on day 6. They reported the mean Hydrox-
ychloroquine serum concentration as 0.46 μg/ml+0.2 (Gautret et al., 
2020a). 
A combination of Hydroxychloroquine and Azithromycin has also 
been evaluated. A total of 80 patients with COVID-19 were enrolled and 
received 200 mg Hydroxychloroquine three times per day for ten days 
combined with 500 mg Azithromycin on day 1 and 250 mg/day the next 
four days. The results showed a significant reduction in the nasopharynx 
viral load (virus-negative rate of 93% on day 8). (Gautret et al., 2020b). 
Contrary to this finding, In a clinical trial on 504 patients with mild to 
moderate covid-19, compared to the standard care group, improvement 
in the clinical condition of the ones who received Hydroxychloroquine 
(400 mg, twice daily) alone or with Azithromycin (500 mg, once daily) 
was not observed (Fatima et al., 2020; Cavalcanti et al., 2020). A clinical 
study by a Chinese team of 62 patients found that taking 400 mg of 
Hydroxychloroquine for five days significantly reduced the fever 
recovery time and cough duration compared to standard treatments 
(Chen et al., 2020d). 
However, in a systematic review and meta-analysis, a study on 12 
observational and randomized trials revealed that the use of Hydroxy-
chloroquine and Chloroquine does not improve clinical outcomes in 
patients with covid-19 (Elavarasi et al., 2020). A large randomized 
clinical trial confirmed Hydroxychloroquine and Chloroquine are not 
recommended to treat hospitalized patients with COVID-19. These 
medications didn’t associate with mortality rate reduction, nor did these 
drugs related to recovery rate improvement (Horby et al., 2020a,b). On 
15th June 2020, Food and drug administration (FDA) defined that 
Hydroxychloroquine and Chloroquine were not beneficial 




Anakinra is a 17 kD biological recombinant, non-glycosylated human 
interleukin-1 receptor antagonist with a short half-life of approximately 
3–4 h and an acceptable safety profile to neutralize hyperinflammatory- 
related to COVID-19 with the severe respiratory syndrome. IL-1 plays a 
significant role in stimulating the production of inflammatory cytokines 
and TNFα. Anakinra blocks the action of IL-1, which leads to inhibit the 
inflammatory responses (King et al., 2020). A cohort study evaluated the 
effect of Anakinra on the severe respiratory syndrome of COVID-19. 
Patients received a dose of 100 mg subcutaneously twice daily for 72 
h, followed by 100 mg once daily for seven days along with a standard 
treatment regimen consist of oral agents (10 days course of Hydroxy-
chloroquine 600 mg/day, five days course of Azithromycin 250 
mg/day), and intravenous antibiotics (Ceftriaxone 1 g/day or Amoxi-
cillin 3 g/day) for seven days. Prophylaxis of thromboembolism was 
considered for all cases. Some patients were a candidate for an intra-
venous bolus 500 mg dose of methylprednisolone. This study deter-
mined a notable decrease in the demand for admission to the Intensive 
Care Unit, invasive mechanical ventilation, and mortality compared 
with standard of care. More patients experienced elevated liver enzymes 
in the Anakinra group than the control group (Huet et al., 2020). A 
previous study exhibited improved respiratory system and reduced 
serum C-reactive protein in 72% of patients with a high-dose of Ana-
kinra (IV) in severe COVID-19, ARDS, and hyper inflammation (Cavalli 
et al., 2020). An open-label study recruited nine patients with moderate 
to severe pneumonia results from COVID-19. Only an old patient 
exhibited an acute respiratory failure after Anakinra that led to dis-
continuing the treatment and ICU admission. Other patients revealed 
good clinical and biological outcomes, in which C reactive protein (CRP) 
levels reduced at day 6 in all cases and controlled in 5 at day 11. Chest 
CT scan showed cessation of lesions development. Patients who received 
Anakinra were alive at the latest follow-up (Aouba et al., 2020). 
5.2. Bamlanivimab 
Bamlanivimab, known as LY-CoV555 and LY3819253, is a neutral-
izing IgG1 monoclonal antibody against the receptor-binding domain of 
SARS-CoV-2 spike protein. So, this monoclonal antibody prevents viral 
attachment and entry of SARS-CoV-2 to the host cells and viral repli-
cation as a result. Within November 2020, the US Food and Drug 
Administration (FDA) provided authorization for emergency use of 
Bamlanivimab therapy for mild-to-moderate COVID-19. This unap-
proved agent is only indicated for use in non-hospitalized adults and 
pediatrics 12 years of age or older with COVID-19 test positive, weight at 
least 40 kg (88 pounds), and who have increased risk for disease pro-
gressing to severe COVID-19 and/or hospitalization, including ≥65 
years of age, underlying chronic medical condition. It has been 
emphasized on prompt administration of Bamlanivimab within ten days 
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of symptom onset or following a positive test. It should be noticed that 
this medication has not an authorization of use in patients with COVID- 
19 related hospital admission or need for oxygen therapy. Bamlanivimab 
is manufactured as a single dose aqueous solution vials in 700 mg/20 ml 
for intravenous infusion over 60 min (https://www.fda.gov/me-
dia/143603/download; https://www.clinicaltrialsarena.com/proje 
cts/bamlanivimab-ly-cov555-for-the-treatment-of-covid-19/). 
Emergency use authorization of this investigational monoclonal 
antibody is based on the results of an interim analysis of an ongoing 
randomized clinical phase 2 trial involved 452 patients with mild- 
moderate COVID-19 in outpatient settings. Of 452 patients were a 
candidate for a single infusion of LY-CoV555, 101 received a dose of 700 
mg, 107 received a dose of 2800 mg, 101 received a dose of 7000 mg and 
143 received placebo. Viral load significantly decreased with Bamlani-
vimab at a dose of 2800 mg vs. placebo. Hospitalization, emergency 
department visits, or death within 28 days of treatment was significantly 
lower than those in placebo (Chen et al., 2020). Any benefit has not been 




As a monoclonal antibody, Bevacizumab acts against Vascular 
Endothelial Growth Factor (VEGF) and is indicated for cancer therapy 
(Wang et al., 2004). VEGF is discussed as the most potent vascular 
penetrance inducers. Bevacizumab binds to VEGF and inhibits the 
constitution of neovascularization, thereby reduces tumor growth 
(Garcia et al., 2020). The last evidence has displayed a high level of 
VEGF in patients with coronavirus disease (COVID-19) compared with 
healthy controls. Factors such as hypoxia, severe inflammation, and 
upregulation of the infected respiratory tract epithelium cause increased 
VEGF levels. Numerous investigations have supported VEGF’s funda-
mental role as a potential clinical goal in acute lung injury (ALI) and 
acute respiratory distress syndrome (ARDS). So that, Bevacizumab, an 
anti-VEGF therapy, may suggest a new approach to the treatment of 
ALI/ARDS due COVID-19. 
In this regard, the efficacy and safety of Bevacizumab have been 
assessed in a single-arm trial. Researchers enrolled 26 patients with 
severe Covid-19 from China and Italy and followed them for 28 days. 
Patients received a single 500 mg dose of Bevacizumab as an intrave-
nous infusion over 90 min with a standard of care. Patients experienced 
considerable increases of PaO2/FiO2 values at day one and day seven 
after Bevacizumab therapy. More than half of the patients discharged. 
Oxygen-support status did not worsen in any patients, and there was no 
mortality report during the follow-up period. Chest computerized to-
mography (CT) or X-ray findings exhibited a substantial decrease in 
lesion areas and ratios within Seven days. Fever disappeared in 3 days in 
patients. Results expressed meaningful increased peripheral lymphocyte 
counts with a significant reduction in CRP levels. Significant improve-
ment occurred in oxygen support in most of the patients. Elevation of 
liver function test was the most common adverse event (Pang et al., 
2020). Thus, researchers described clinical trials for the evaluation of 
Bevacizumab on COVID-19. 
An open-label clinical trial targeted 27 COVID-19 patients and pre-
scribed Bevacizumab 500 mg + 0.9% sodium chloride for 7 days 
(https://clinicaltrials.gov/ct2/show/NCT04275414? 
term=NCT04275414&draw=2&rank=1). Another one is a randomized 
clinical trial on Bevacizumab’s efficacy in Severe Patient with COVID-19 
(https://clinicaltrials.gov/ct2/show/NCT04305106). 
5.4. Sarilumab 
Sarilumab, as a humanized monoclonal antibody, inhibits the 
interleukin-6 receptor. An open-label study assessed Sarilumab’s safety 
and efficacy in patients with severe COVID-19 pneumonia and hyper 
inflammation. Twenty-eight patients received an intravenous infusion of 
Sarilumab at the single dose of 400 mg in addition to standard treat-
ment, and 28 patients, as a control group, treated with standard of care. 
Based on the local institutional standard of care, all patients received 
oral lopinavir/ritonavir, hydroxychloroquine, and a course of azi-
thromycin on admission. Supportive care with supplemental oxygen 
and/or ventilation support with continuous positive airway pressure 
was provided based on the physician’s decision. Sarilumab associated 
with non-significant clinical improvement and die compared to control 
at day 28. There was no correlation between IL-6 serum concentration 
and the other clinical outcome predictors. Time to the normalization of 
C reactive protein levels was significantly shorter with Sarilumab. 
Considering adverse events, the infection and pulmonary embolism rate 
were not different between groups (Della-Torre et al., 2020). 
Sanofi and Regeneron conducted a multicenter, double-blind, and 
phase 3 trial to evaluate the clinical benefit of intravenous Sarilumab in 
three arms, including 161 patients in 200 mg dose, 173 patients in 400 
mg dose, and 86 patients in placebo. Unfortunately, ill patients with 
severe COVID-19 did not improve outcomes throughout evaluation than 
placebo added to standard care. 24–29% of treated patients with Sar-
ilumab and 24% of patients who received placebo expressed severe 
adverse effects. Serious infection occurred in 11–13% of treated cases 
and 12% of the placebo group (https://clinicaltrials.gov/ct2/-
show/NCT04327388). An observational clinical study has reported 
Sarilumab therapy’s outcome in 53 patients with SARS-CoV-2 associated 
with severe pneumonia. All patients received an intravenous infusion of 
Sarilumab at a dose of 400 mg on day 1and followed for 14 days. 
Additional administration was at the clinical decision. All patients who 
were positive for SARS-CoV-2 concomitantly received lopinavir/rito-
navir or darunavir/ritonavir; Hydroxychloroquine; Azithromycin, and a 
prophylactic dose of heparin. Glucocorticoids could be used for patients 
who were admitted to the ICU. Of 53 cases, 39 were treated in medical 
wards and 14 in ICU. 7 (17.9%) medical ward admitted patients needed 
to ICU admission, and 4 of whom were readmitted to the ward within 
5–8 days. Most of the medical inpatients showed considerable 
improvement in medical outcome at 19 days median follow-up, and 
most of the cases no longer required oxygen support. More than half of 
the patients were discharged to the ward (Gremese et al., 2020). 
5.5. Thalidomide 
Thalidomide, an anti-inflammatory and immune-modulating drug, 
has been used to treat multiple inflammatory diseases, such as Crohn’s 
disease, Behcet’s disease, and myeloma (Tu et al., 2020). It induces the 
degradation of messenger RNA in blood cells and reduces tumor necrosis 
factor-α (TNFα). The secretion of interleukins (IL), such as IL-12, and 
activation of natural killer cells can also be increased under the influence 
of Thalidomide (Rosa and Santos, 2020). Other mechanisms include 
suppressing angiogenesis, preventing DNA damage caused by free rad-
icals, and altering the cellular adhesive molecules expression (Khalil 
et al., 2020). Fortunately, its side effects are limited, including drowsi-
ness, dizziness, and rash (Franks et al., 2004). Thalidomide has been 
considered to reduce inflammation related to COVID-19. Meanwhile, in 
a case study, a 45-year-old woman positive covid-19 was prescribed 
Thalidomide at a dose of 100 mg/day and low-dose methylprednisolone 
(40 mg every 12 h). The patient’s clinical conditions as oxygen index, 
anxiety, nausea, vomiting, improved during three days, and cytokine 
levels returned to normal after a week (Chen et al., 2020b). There are 
also two clinical trials working on Thalidomide, with the results still not 
published. Both are planned to use 100 mg/d for 14 days and 
are in phase 2 (https://clinicaltrials.gov/ct2/show/NCT04273581?term 
=NCT04273581&draw=2&rank=1) (https://clinicaltrials.gov/ct2/-
show/NCT04273529?term=NCT04273529&draw=2&rank=1). 
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5.6. Tocilizumab 
Tocilizumab is an FDA-approved immunosuppressive drug that is 
effective against Rheumatoid arthritis, systemic juvenile idiopathic 
arthritis, and chimeric antigen receptor (CAR)-cell-induced cytokine 
release syndrome (CRS) (Genentech, 2017). It is a monoclonal antibody 
against the cytokine Interleukin 6 receptor. Tocilizumab is a competitive 
inhibitor of IL-6-mediated signaling. Interleukin 6 plays a crucial role in 
inflammation and immune responses, and its overexpression has path-
ological effects on chronic inflammation and autoimmunity (Tanaka 
et al., 2014). Notably, headache, dizziness, upper abdominal pain, 
mouth ulcers, neutropenia, thrombocytopenia, increased liver enzymes, 
increased total cholesterol, and triglycerides are common complications 
of Tocilizumab (Zhang et al., 2020a). 
Reportedly, in COVID-19, inflammatory cytokines, including inter-
leukin 6, 10, and TNFα increase, leading to cytokine storms and acute 
symptoms in patients, progressing to cardiovascular collapse, multiple 
organ dysfunction, and death. Tocilizumab binds to interleukin-6 re-
ceptors, interrupts cellular signals transduction pathway, and subse-
quently decreases inflammatory responses (Zhang et al., 2020a). 
In a study on 15 COVID-19 patients, eight were given Tocilizumab 
combined with prednisolone, and five patients received Tocilizumab 
alone, twice or more. In all patients, serum interleukin-6 levels 
decreased significantly after Tocilizumab treatment. Although the CRP 
rate returned to normal rapidly, it was not significant for four critically- 
ill patients who took only one dose of Tocilizumab (Luo et al., 2020). 
However, in a cautionary case report working on two patients, despite a 
decrease in CRP post-Tociizumab therapy, the disease developed. It 
should be noted that Tocilizumab may worsen the clinical course of 
patients by adding to immunosuppression. Elevated Interleukin 6 levels 
may be a compensatory mechanism for impaired viral responses; 
therefore, Tocilizumab-induced decrease in Interleukin 6 can promote 
increased viral replication (Radbel et al., 2020). Another group working 
on 21 COVID-19 patients prescribed 400 mg (up to 800 mg) Tocilizumab 
along with routine treatments. Symptoms improved dramatically within 
a few days. Seventy-five percent of patients needed low oxygen therapy. 
The rate of lymphocytes returned to normal at 52.6%. Furthermore, 
interleukin 6 and CRP levels were significantly reduced in 90% of pa-
tients, and all cases were discharged on average 15.1 d after Tocilizumab 
therapy (Xu et al., 2020a). Additionally, Zhang et al. reported the first 
case of COVID-19 in a Multiple Myeloma, which has been successfully 
treated after Tocilizumab therapy (8 mg/kg administered IV, one time). 
Of note, after Tocilizumab administration, a fluctuation in Interleukin 6 
levels appeared. It decreased gradually and then increased to the peak, 
followed by another decrease to a low level, which can be attributed to 
the recovery of the normal T cells (Zhang et al., 2020c). A 45-year old 
COVID-19 positive patient with Sickle cell disease was also treated with 
Tocilizumab and other standard treatments in France. They prescribed 8 
mg/kg Tocilizumab; on day three, an improvement of the patient’s 
general condition was observed, and on day five, he was discharged (De 
Luna et al., 2020). The effect of Tocilizuman on mortality and/or 
invasive mechanical ventilation in 30 severe COVID-19 patients 
compared with those in 176 patients who were not treated with Toci-
lizumab. This retrospective case-control study revealed that treatment 
with Tocilizumab results in a considerably lower mortality rate and/or 
invasive mechanical ventilation (Klopfenstein et al., 2020). 
Generally, there are other cases where favorable changes were 
observed in CT findings, CRP and Interleukin 6 levels, fever, and 
lymphocyte rate after taking Tocilizumab (Di Giambenedetto et al., 2020; 
Michot et al., 2020). However, several clinical trials are actively 
inspecting Tocilizumab to determine its safety and efficacy in 




Interferons (IFN) discovered by virologists in 1957 are essential 
components of the immune system against viral infections. Most cells 
produce type I IFNs (α and β) as a direct response to viruses, while type II 
IFN (λ) is produced by activated natural killer (NK) cells and T cells. 
They hinder viral replication, including viral entry, uncoating, mRNA 
synthesis, protein synthesis, and subsequently reduce the viral load 
(Meng et al., 2020; Sainz Jr et al., 2004). Clinically, IFN therapy has 
already been approved for cancers, autoimmune diseases, and hepatitis 
B and C (Mantlo et al., 2020). Moreover, numerous studies have been 
conducted on MERS-CoV and SARS-CoV, in vitro and in vivo. An in vitro 
study in 2003 assessed recombinant IFN against SARS-CoV and showed 
their inhibitory and prophylactic protection, reporting the 18 IU/ml as 
EC50 (Cinatl et al., 2003). Furthermore, another group has suggested a 
synergistic antiviral relationship between type I and type II IFNs. They 
demonstrated a potent 105-fold inhibition on SARS-CoV replication by 
IFN-β and λ, at a low concentration of 100 u/ml each (Sainz Jr et al., 
2004). Meanwhile, there are retrospective studies on SARS-CoV and 
MERS-CoV, which have used IFNs in combination with different agents 
(Song et al., 2020). 
Although IFNs were suggested to be systemically efficient in SARS 
and MERS-CoV, for example, improving pulmonary function or delaying 
mortality, they generally failed to significantly improve the disease in 
humans (Sallard et al., 2020). Despite similarities between coronavi-
ruses, in a report, researchers have demonstrated that IFN production is 
not induced efficiently in response to SARS-CoV-2, which leads to the 
prevention of innate immune response and higher viral levels. There-
fore, exogenous IFN might be more efficient for treating SARS-CoV-2 
infection (Meng et al., 2020; O’Brien et al., 2020). 
An experiment on SARS-CoV-2, suggesting IFN pre-treatment, incu-
bated Vero E6 cells with 1000 units/ml of recombinant IFN-α 18 h 
before infection. The results showed a significant reduction in viral 
replication, massive drops in viral titer, and a considerable deficit in 
viral nucleocapsid protein production (Lokugamage et al., 2020). There 
is also a medical staff trial indicating that recombinant IFN-α nasal drops 
can protect susceptible healthy people. They included 2944 participants 
in two high- and low-risk groups. After 28 days of following up new 
COVID-19 cases, positive pulmonary images, and fever/respiratory 
symptoms were zero, confirming IFN-α′s protective effects (Meng et al., 
2020). Furthermore, a group in America investigated antiviral activities 
of type I Interferons on SARS-CoV-2 in vitro. They treated infected Vero 
cells with IFN-α and β at different concentrations (0.49–250 IU/ml). The 
results indicated no detectable virus titers and determined the EC50 of 
IFN-α and β as 1.35 IU/ml and 0.75 IU/ml, respectively (Mantlo et al., 
2020). 
A double-blind placebo-controlled phase 2 trial studied the safety 
and efficacy of inhaled nebulized interferon beta-1a in COVID-19 
infection-related hospitalized patients. Forty-eight patients were ran-
domized to receive inhaled nebulized interferon beta-1a (6 Million 
units/day) and 50 to inhale placebo for 14 days. Clinical improvement, 
on the WHO Ordinal Scale for Clinical Improvement (OSCI), was more 
than two times in inhaled interferon beta-1a compare to placebo on day 
15 or 16 (odds ratio (OR) 2.32; 95% confidence interval (CI), 1.07–5.04; 
p = 0.033) and three-times greater on day 28 (OR 3.15, 95% CI 
1.39–7.14, p = 0.006). Also, inhaled interferon beta-1a leads to more 
recovery of activities with no limitation (hazard ratio (HR) = 2.19; 95% 
CI, 1.03–4.69; p = 0.043) vs. placebo. Inhaled interferon beta-1a 
resulted in a reduction of severe disease development (OR 0⋅21; 95% 
CI 0⋅04–0⋅97]; p = 0⋅046). Headache was more commonly experienced 
by patients in the interferon and placebo group. The mortality report 
belonged to the placebo group (three patients) (Monk et al., 2020). A 
randomized open-label, Phase 2 trial enrolled 127 COVID-19 related 
hospitalized patients to treat a combination antiviral regimen or lopi-
navir/ritonavir as a control. Depend on hospital admission time from 
onset of symptoms, which was <7 days or ≥7 days, and hospitalized 
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patients were a candidate for 14 days triple or dual therapy, respec-
tively. Fifty-two cases received subcutaneous interferon beta-1b 8 
million units every second day, lopinavir/ritonavir, and ribavirin; 34 
cases received lopinavir/ritonavir and ribavirin. Forty-one in the control 
group received lopinavir/ritonavir unrelated to time from onset of 
symptom to hospitalization. The median time to negative nasopharyn-
geal swab was substantially shorter in combination therapy. The com-
bination group revealed meaningful clinical improvement, according to 
the National Early Warning Score 2 (NEWS2) and Sequential Organ 
Failure Assessment (SOFA) score, and considerably shorter hospital stay. 
Prominent antiviral activity and clinical effect resulting from treatment 
with a combination antiviral regimen less than seven days from the 
onset of symptom indicate that interferon beta-1b was a crucial 
component in combination therapy (Hung et al., 2020). 
A cohort study of 77 positive COVID-19 patients in China assessed 
patients treated with IFN-a2b 5 million international units twice a day, 
Umifenovir 200 mg three times a day, as well as a combination of IFN- 
a2b and Umifenovir. Outcomes recommended IFN-a2b therapy with or 
without Umifenovir resulted in a faster rate of viral clearance from the 
respiratory tract, decreased inflammatory cytokine and biomarker 
levels, including IL-6 and CRP (Zhou et al., 2020a,b). 
6. Angiotensin II receptor blocker 
6.1. Losartan 
Losartan, an angiotensin II (Ang-II) receptor antagonist, is used to 
treat heart failure, high blood pressure, and diabetic kidney diseases. In 
competition with angiotensin II, Losartan inhibits its binding to the AT1 
receptor, thereby counteracts the physiological effects of Ang-II, which 
consequently dilates smooth blood vessels and lowers blood pressure 
(Zeinalian et al., 2020). Analysis of clinical characteristics of covid-19 
patients suggesting that hypertension has been responsible for 60.9% 
of deaths. Otherwise, coronaviruses transfer their genetic materials 
through fusing to the host cell, mediated by binding to the ACE2 re-
ceptor (Li et al., 2020a). In the outbreak of SARS-CoV in 2003, it was 
identified that ACE2 knockout mice had significantly lower viral loads in 
the lung following infection. They showed that treatment with Losartan 
15 mg/kg attenuated lung injuries (Kuba et al., 2005). 
Therefore, there is a perspective if ACE2 blockade act as a viable 
approach to attenuate COVID-19. In this regard, there are two double- 
blinded clinical studies actively working on Losartan in hospitalized 
and non-hospitalized COVID-19 patients. Both are in phase 2. About 200 
hospitalized patients randomly are assigned to receive Losartan 50 mg 
daily or placebo for seven days. The primary outcome is the evaluation 
and measurement of PaO2 or SaO2/FiO2 ratio after seven days 
(https://clinicaltrials.gov/ct2/show/NCT04312009). The other one is 
conducted in 580 non-hospitalized COVID-19 cases to intake Losartan 
25 mg per day or placebo for ten days with the primary outcome of 
hospital admission within 15 days of treatment (https://www.clin-
icaltrials.gov/ct2/show/NCT04311177). 
7. Bradykinin B2 receptor antagonist 
7.1. Icatibant 
Icatibant is a bradykinin B2 receptor inhibitor and available in the 
US and Europe as a therapy for hereditary angioedema. Bradykinin, as a 
potent inflammatory mediator, causes more dilation and permeability of 
blood vessels, leading to fluid accumulation in the interstitial tissue. 
Icatibant binds to B2 receptors and hinders bradykinin functionality 
(Farkas, 2016). 
It is revealed that COVID-19 enters the host cells through binding to 
the ACE2 receptor, highly expressed on pulmonary cells. Following virus 
activity, the ACE2 receptors will be occupied, and active ACE2 will 
reduce in the body, subsequently, and of note, ACE2 is responsible for 
hydrolyzing the active bradykinin metabolite [des-Arg973] (DABK). 
Therefore, as a side effect, COVD-19 activates this bradykinin system, 
which leads to fluid extravasation and leukocyte recruitment to the lung, 
which persists in pulmonary edema subsequently. This will deteriorate 
the lung damages caused by the virus. Thus, it seems that targeting the 
bradykinin system may be a new therapeutic approach for patients with 
COVID-19. Exploratory research investigated the effect of Icatibant in 9 
CVID-19 infected patients. Icatibant 30 mg was injected subcutaneously 
every 6 h for three doses and lead to a substantial reduction in oxygen 
supplementation with no serious adverse events. (Tolouian et al., 2020; 
van de Veerdonk et al., 2020). Although there is no randomized clinical 
evaluation of Icatibant yet, it has been introduced as a potential 
candidate in purpose. 
8. Corticosteroids 
Corticosteroids, including glucocorticoids and mineralocorticoids, 
are produced by the adrenal cortex. They have been proved as immu-
nosuppressive and anti-inflammatory drugs for the treatment of condi-
tions such as asthma, allergy, septic shock, multiple sclerosis, and lung 
tissue disorders. Corticosteroids alter gene transcription through bind-
ing to a particular receptor in target cells. However, their use is limited 
by their massive probable side effects as hyperglycemia, hypertension, 
infection, osteoporosis, growth retardation, skin atrophy, glaucoma, and 
cataract (Ramamoorthy and Cidlowski, 2016; Song et al., 2020; Wang 
et al., 2020d). Systemic inflammation is an adverse outcome caused by 
coronaviruses, which persists after viral clearance. So, theoretically, 
corticosteroids can be potential candidates for suppressing lung in-
flammations. There are some reviews summarizing reports on SARS and 
MERS, revealing no benefits of corticosteroids. In general, the studies 
suggest associations between corticosteroid administrations and disease 
deterioration (worsening pulmonary conditions) and mechanical 
ventilation requirements, delayed viral clearance, avascular necrosis, 
and diabetes. They have called it a double-edged sword (Nasim et al., 
2020; Russell et al., 2020). Since the outbreak of COVID-19, new studies 
have been designed on Corticosteroids. In an in vitro study on VeroE6 
cells, Ciclesonide has been introduced as a safe corticosteroid to reduce 
viral replication and host inflammation by EC90 = 6.3 μM (Matsuyama 
et al., 2020). A clinical study reviewed 46 patients with severe 
COVID-19, in which 26 patients received 1–2 mg/kg/d methylprednis-
olone intravenously for 5–7 days. Results revealed faster improvement 
of oxygen saturation, better absorption degree of the focus in chest CT, 
and shorter time to overcome hyperthermia (Wang et al., 2020d). 
Nevertheless, a report on 31 patients with 11 administrated corti-
costeroids indicated no statistically significant differences in treated 
patients and the non-treated. They investigated the virus clearance time, 
hospital length of stay, and duration of symptoms, and there was no 
improvement compared with the control patients (Zha et al., 2020). 
Moreover, an open-labeled, randomized controlled trial enrolled 48 
cases from Chongqing Public Health Medical Center, China. The subjects 
are assigned in two groups, the intervention group, which receives an 
intravenous injection of 1–2 mg/kg/day methylprednisolone for three 
days, and the control group. The study is examined the timing of clinical 
improvement, duration of mechanical ventilation and hospitalization, 
rate of adverse effects, and mortality. The results have not yet been 
revealed (Zhou et al., 2020a,b). As of now, the use of corticosteroids in 
patients with COVID-19 is controversial since the WHO and the Centers 
for Disease Control and Prevention (CDC) generally recommend that 
glucocorticoids not be used in COVID-19 pneumonia unless in specific 
comorbid clinical conditions, e.g., exacerbation of chronic obstructive 
pulmonary disease (Song et al., 2020). 
The RECOVERY trial is an ongoing, open-label, controlled trial 
conducted on hospitalized patients with COVID 19 in the UK. The pri-
mary endpoint was mortality rate at 28 days. The study assigned 2104 
patients to receive Dexamethasone, oral or intravenous, at the dose of 6 
mg daily for ten days, plus standard care, and 4321 patients to receive 
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usual care alone. According to the preliminary analysis report, of 6425 
patients, 22.9% of patients (n = 482) in the dexamethasone group and 
25.7% (n = 1110) in the standard care group died within 28 days of 
randomization (P < 0.001). Compared to the usual care group, the 
dexamethasone group had a lower incidence rate of mortality among 
patients who required invasive mechanical ventilation (29.3% vs. 
41.4%) and oxygen supplement (23.3% vs. 26.2%). A significant sur-
vival benefit was not found in patients who did not receive respiratory 
support (Horby et al., 2020a,b). 
The World Health Organization (WHO) rapid evidence appraisal for 
COVID-19 therapies (REACT) assessed the association between corti-
costeroids and mortality rate in critically ill patients infected with 
COVID-19. This meta-analysis includes seven trials (DEXA-COVID 19, 
RECOVERY, REMAP-CAP, CoDEX, CAP COVID, COVID STEROID, and 
Steroids-SARI) pooled data. Of 1703 patients who had participated in 
the analysis, 678 received corticosteroids (3 trials Dexamethasone, three 
trials Hydrocortisone, one trial Methylprednisolone) 1025 had received 
standard of care or placebo. 222 patients (32%) in the corticosteroid 
group and 425 patients (40%) in the standard care or placebo group died 
(p < 0.001) within 28 days. Dexamethasone and hydrocortisone were 
the same in mortality rate reduction (Sterne et al., 2020). 
At the same time, WHO released the guideline of corticosteroids for 
COVID-19 in which systemic administration of Dexamethasone 6 mg 
daily or Hydrocortisone 150 mg (e.g., 50 mg every 8 h), or Prednisone 
40 mg, or Methylprednisolone 32 mg (e.g., 8 mg every 6 h or 16 mg 
every 12 h) for 7–10 days has been recommended for patients with se-
vere and critical COVID-19 (https://www.who. 
int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1). 
Early administration of corticosteroids at a low dose for the short 
term has been evaluated in 475 hospitalized patients with non-severe 
COVID 19 related pneumonia. Methylprednisolone 20 mg per day or 
40 mg per day for 3–5 days was prescribed intravenously for 50 patients, 
and five patients received prednisone 20 mg per day for three days. 420 
patients did not receive corticosteroid therapy. The length of fever, virus 
clearance, and hospital stay were significantly prolonged in the corti-
costeroid group. More patents in the corticosteroid group progressed to 
severe disease. Antimicrobial therapy was more remarkable in the 
corticosteroid group. So worse outcomes are expected from corticoste-
roid therapy in non-severe COVID-19 pneumonia (Li et al., 2020). 
Another retrospective study evaluated the effect of early adminis-
tration of corticosteroids on mortality rate and mechanical ventilation in 
1806 hospitalized patients with COVID 19. Of 1806 patients, 140 
received corticosteroids within the first 48 h of admission. Corticoste-
roid therapy in patients with initial C-reactive protein (CRP) 20 mg/dL 
or more significantly decreased mortality or mechanical ventilation. In 
contrast, mortality or mechanical ventilation became more significant in 
patients with a CRP level of less than 10 mg/dL (Keller et al., 2020). 
Careful interpretation of these findings needs to perform further 
randomized clinical studies. 
9. Anthelmintic 
9.1. Ivermectin 
Studies on SARS-CoV proteins have revealed an important role for 
importin (IMP) α/β1 during infection, impacting host cell division. 
There is an FDA-approved drug termed Ivermectin that has been 
licensed as an anti-parasite and antiviral agent (Caly et al., 2020). 
Ivermectin inhibits IMP α/β1-mediated nuclear import, specifically nu-
clear transport of viral proteins. Subsequently, it can suppress several 
RNA virus replication, including HIV, the chikungunya virus, and the 
yellow fever virus (Patrì and Fabbrocini, 2020). Based on the similarity 
of SARS-CoV and SARS-CoV2, Ivermectin could be a potential drug 
candidate for controlling COVID-19. An in vitro study has been designed 
towards Ivermectin antiviral activity on Vero/hSLAM cells infected with 
COVID-19. They proved its efficacy in a single dose for 48 h, observing 
93% reduction in viral RNA presented in the supernatant at 24 h and 
99% reduction in cell-associated viral RNA equivalent to a ̴5000-fold 
reduction by 48 h (Caly et al., 2020). Ivermectin is also a safe drug, 
which is a study of phase 3 clinical trials on dengue patients in Thailand; 
it was introduced to be secure enough (Caly et al., 2020). Also, in a 
meta-analysis working on its high doses, its safety was strongly 
confirmed even beyond its prescribed doses (Navarro et al., 2020). 
Nonetheless, the use of Ivermectin to combat COVID-19 would depend 
on further pre-clinical and clinical trials. There is even a hypothesis 
suggesting its combined use with Hydroxychloroquine (Patrì and Fab-
brocini, 2020). A study retrospectively analyzed the data of 280 patients 
with COVID-19 related infection admitted to four hospitals in Florida, 
173 received Ivermectin (200 mcg/kg single dose plus usual care, the 
dose could be repeated at the physician’s discretion on day 7 after 
treatment initiation) and 107 received usual treatment. All-cause mor-
tality was substantially lower in Ivermectin patients (OR, 0.27; 95% CI, 
0.09–0.80; P, 0.03), also patients with severe pulmonary disease treated 
with Ivermectin had lower mortality rate (38.8% vs. 80.7%; OR, 0.15; 
95% CI, 0.05–0.47; P, 0.001). Data analysis didn’t demonstrate any 
significant differences in extubation rate (36.1% vs. 15.4%; OR, 3.11; 
95% CI, 0.88–11.00; P, 0.07) and hospital stay (Cepelowicz Rajter et al., 
2020). A trial of 116 patients with mild to moderate COVID-19 infection 
compared combination therapy of Ivermectin and Doxycycline with 
Hydroxychloroquine plus Azithromycin. Sixty patients treated with 
Ivermectin and Doxycycline had a better recovery to symptom-free and 
shorter time to recovery. 
Additionally, Ivermectin-Doxycycline was better tolerated vs. 
Hydroxychloroquine plus Azithromycin therapy. Based on these results, 
the authors believe Ivermectin can be considered an acceptable choice 
for infected patients with mild to moderate COVID-19 (Taiub et al., 
2020). One hundred forty patients with COVID-19 have been investi-
gated in a randomized control study. 70 Participants received oral 
Ivermectin 200 mcg daily for two to three days plus oral doxycycline 
100 mg twice daily for 5–10 days in addition to standard treatment, and 
70 participants in the control group received standard therapy. Iver-
mectin group had less progression to more advanced disease and mor-
tality rate, also significantly decreased time to recovery (Hashim et al., 
2020). Currently, clinical trials at various stages of completion have 
been registered in the European Union Clinical Trials Register and the 





Nitazoxanide has a broad-spectrum antiviral and anti-parasitic ac-
tivity. Nitazoxanide targets regulatory mechanisms involved in virus 
replication (Mahmoud et al., 2020). This thiazole derivative has been 
clinically developed for the treatment of patients with viral respiratory 
infections. In in vitro studies, Nitazoxanide inhibited viral N protein 
expression in the MERS-CoV and other human coronaviruses. Further-
more, Nitazoxanide inhibits the pro-inflammatory cytokines and inter-
leukin 6 in peripheral blood mononuclear cells in mice. 
Lately, Kelleni has suggested combination therapy of Nitazoxanide 
with azithromycin to treat COVID-19 (Kelleni, 2020). Besides, Pepper-
rell et al. summarize the reported clinical investigations about Nita-
zoxanide to define the safety of this drug for the treatment of COVID-19. 
Presently, 14 clinical trials are being investigated for using Nitazoxanide 
alone or in combination with Ivermectin or Hydroxychloroquine to 
manage patients with COVID-19 (Mahmoud et al., 2020; Pepperrell 
et al., 2020). 
In a placebo-controlled trial, 392 patients were randomly allocated 
to receive Nitazoxanide 500 mg three times a day for five days or pla-
cebo group. On day 5, symptom relief in 194 patients treated with 
Nitazoxanide did not significantly differ from 198 patients in the 
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placebo group, although, after seven days of therapy, symptom relief in 
the Nitazoxanide group was considerably better than the control group. 
Viral load was reduced substantially with Nitazoxanide following five 
days of treatment. Nitazoxanide did not associate with serious adverse 
events or death, and its early use is suggested by the authors (Rocco 
et al., 2020). Another double-blind phase 3 clinical study is related to the 
efficacy evaluation of Nitazoxanide extended-release tablet in mild or 
moderate cases of COVID-19. In this undergoing research, participants 
will receive Nitazoxanide or placebo bidaily for five days. Recovery time 




Emetine is a protein inhibitor approved for the treatment of amoe-
biasis as anti-protozoan. It also inhibits malaria, blocking its protein 
synthesis by binding to the Plasmodium falciparum’s ribosomal E site. 
Besides, Emetine processes antiviral activity against a broad range of 
RNA and DNA viruses, specifically coronaviruses as SARS-CoV and 
MERS (Choy et al., 2020). A report against four strains of coronaviruses 
declared EC50 values ranging from 0.12 to 1.43 μM, with the MERS 
being 0.34 μM (Bleasel and Peterson, 2020). Thus, a study has examined 
Emetine on SARS-CoV2 in vitro, working on Vero E6 cells infected by the 
virus. They estimated its EC50 at 0.46 μM. Furthermore, this study 
observed its synergism with Remdesivir, achieving 64% inhibition of 
viral yield with the subsequent reduction in the effective concentration 
of compounds and consequent side effects (Choy et al., 2020). Notice-
ably, there is no in vivo or clinical trial of Emetine on COVID-19. 
11. H2 blocker 
11.1. Famotidine 
Famotidine is an H2 receptor antagonist, which inhibits the secretion 
of gastric acid. There is a hypothesis that Famotidine binds to papain- 
like protease, and the SARS-CoV-2 genome may encode protease. 
Although no evidence supports this hypothesis, Famotidine was 
administrated because of low side effects and bioavailability (Janowitz 
et al., 2020). A systematic review assessed the results of 5 types of 
research consisting of 2 case series and three cohort studies in a clinical 
outcome case following Famotidine therapy. Patients in 3 cohort studies 
and 1 case series were hospitalized with COVID-19 and in 1 case series 
did not. A different daily dose of Famotidine was used in the range of 20 
mg–320 mg for 5–28 days. Famotidine significantly decreased 
in-hospital mortality, rate of mortality/intubation, progression to severe 




Heparin is a glycosaminoglycan, as an anticoagulant, prevents blood 
clot formation. Heparin inhibits the activation of the fibrin stabilizing 
factor through a trombone, which prevents the fibrin clot formation. 
Anticoagulants, in particular heparin, are suggested for patients with 
severe COVID-19 (Driggin et al., 2020; Gozzo et al., 2020). Since severe 
hypercoagulability occurs in these patients, early treatment with anti-
coagulation may decrease coagulopathy and reduce the risk of organ 
damages. The effect of heparin in COVID-19 is determined by lots of 
investigations describing its pleiotropic activity. The acute lung injury 
has a high level of D-dimer and fibrinogen, associated with the hyper-
coagulable phase. Besides, patients with severe disease and prolonged 
immobility are exposed to a high risk of venous thromboembolism 
(VTE), and acute pulmonary embolism (PE) or deep vein thrombosis 
(DVT) may be experienced in patients with mechanical ventilation. 
Numerous randomized controlled trials have been designed to assess 
anticoagulation risks and efficacy in patients with COVID-19 (Buijsers 
et al., 2020; Fletcher-Sandersjöö and Bellander, 2020). By its spike (S) 
protein, SARS-CoV-2 binds to the TMPRSS2 receptor, and this viral entry 
is facilitated by the ACE-2 receptor (Hoffmann et al., 2020a). In a similar 
mechanism, SARS-CoV-1 enhances the expression of fibroblast growth 
factor (FGF), fibrinogen gamma chain (FGG), and serine protease genes 
(SERPIN), and eventually upregulation of coagulation cascade factors as 
a result (Giannis et al., 2020). 
Moreover, a cohort study on 184 hospitalized patients with COVID- 
10 pneumonia evaluated the thrombotic event. All patients received 
standard doses of thromboprophylaxis. The researchers suggest throm-
bosis prophylaxis and high-prophylactic doses for all patients admitted 
to the intensive care unit (Klok et al., 2020). 
13. Conclusion 
The emergence of novel viruses during the last two decades and their 
pandemic has called for a need for massive experiments in a short time. 
As an essential step, drugs can be developed through three strategies:  
1. Directly developing a new viral-specific drug based on the genomic 
and pathological information. Theoretically, these drugs would 
exhibit targeted effects, but the procedure may last several years, 
which is not appropriate for a pandemic.  
2. Screening databases for potential molecules with therapeutic effects 
that introduce good candidates for virtual functions for further 
investigations.  
3 Using pre-existing components. That would be the fastest way with 
known safety and side effects, the dosage used, absorption, and 
metabolic characteristics (de Wilde et al., 2014; Dyall et al., 2014; 
Wu et al., 2020a). The novel coronavirus, SARS-CoV-2, is the latest 
outbreak with a serious threat to the global public, and to date, there 
is no approved therapeutic drug or vaccine against it. Many in-
vestigations have been designed on broad-spectrum inhibitors, in 
vitro, in vivo, and clinical. The drugs described here belong to 12 
different pharmaceutical drug classes where antivirals are the most 
used, which all are summarized in Table 1. Table 2 summarized the 
physical and chemical properties and structure of these agents. 
Remdesivir is the only drug that WHO has issue its emergency use 
authorization. Darunavir, Oseltamivir, and Arbidol showed no 
improvement and was introduced as ineffective. Notably, despite posi-
tive therapeutic effects, Corticosteroids, the double-edge sward group, 
are limited by WHO for specific comorbid conditions, and the FDA also 
stops the use of Chloroquine and Hydroxychloroquine. Their clinical 
trials are paused on 25 May 2020. Meanwhile, Ribavirin and Azi-
thromycin are introduced as promising candidates for co-treatment and 
other therapies. This simultaneous combination is an excellent approach 
to employ different pathways in a short time. 
Beclabuvir, Saquinqvir, Ledipasivir, Velpatasivir, Galdesivir, Nita-
zoxanide, and Indinavir are other drugs shown to be efficient in silico 
and are potential candidates for further in vitro and clinical 
investigations. 
At this time, there are no approved, safe, and effective pharmaco-
logic agents to treat COVID-19 infected patients, and research of all 
potential medications is essential to fight the virus. Consequently, 
various pharmacologic agents are now ordered, targeting different 
phases of virus activity. In this respect, combination therapy may be 
useful to inhibit virus activity and complications as a consequence. 
There are inconsistent reports about the efficacy of candidate medica-
tions. Currently, further clinical studies should be urgently designed to 
evaluate the pharmacotherapy agents that seem to be promising and 
determine the most appropriate modality to diminish the spread of this 




Potential therapies for COVID-19 treatment as drug repositioning.  
Agent Classification Target Treatment Dosage Common side effects Approved for Clinical trials (Based 
on Clinicaltrials. 
gov) 
Contraindication Comments for 
COVID-19 




800 mg daily Nausea, Vomiting, Diarrhea, 
Stomach pain, Headache, 
Rash, 
HIV (NCT04252274) Co-administration with CYP3A 
highly dependent drugs are 
associated with serious and/or 
life-threatening events. 
Positive effects in 
combination with 
other antivirals 
Oseltamivir (Tamiflu) Antiviral Neuraminidase 
inhibitor 
75 mg twice a day Nausea, Vomiting, Headache, 
Pain; Sudden confusion, 




Hypersensitivity to Oseltamivir 
or any component of the 
formulation. 
Ineffective 
Umifenovir (Arbidol) Antiviral Hemagglutinin 
inhibitor 
200 mg three times 
daily 
Limited allergic reactions Influenza A and B (NCT04260594) 
(NCT04350684) 
Increased sensitivity to the 




Favipiravir (Avigan) Antiviral RdRp inhibitor 1600 mg twice daily 
on day 1 and 600 mg 
twice daily on days 
2–14 
Decreased RBC production, 





Using in women who might be 
or are pregnant 
Symptoms 
reduction 
Remdesivir (Veklury) Antiviral RdRp inhibitor 200 mg/dose Swelling, Bruising or bleeding 
around the IV needle, Rash, 
Diarrhea, Renal impairment, 
Hypotension and increased 
hepatic enzymes 




Hypersensitivity to Remdesivir 




Ribavirin (Virazole) Antiviral Viral protein 
synthesis inhibitor 
6 g over 12–18 h 
daily, Oral inhalation 
Anxiety, Cough or hoarseness, 
Diarrhea, Sleeplessness, 
Headache, Vomiting, Nausea, 






Hypersensitivity to ribavirin or 
any component of the 
formulation; Pregnant women 
or may become pregnant 
effective as an add- 
on therapy 
Nafamostat mesylate Antiviral Serine protease 
inhibitor 
0.1–0.2 mg/kg/h of 
mixed with 5% DW 









Heparin Improve patient’s 
conditions 
effectively 
Camostat mesylate Antiviral Serine protease 
inhibitor 
2 × 100 mg pills 3 
times daily for 5 days 











Antiretroviral Protease inhibitor, 
CYP4503A 
inhibitor 
400 mg/100 mg; or 
200 mg/50 mg 
Headache. 
Stomach pain or Diarrhea, 
Chest pain or pressure. 
Dizziness or passing out. 
HIV (NCT04330690) 
(NCT04409483) 
Hypersensitivity to lopinavir, 
ritonavir, Pregnancy; hepatic 
or renal failure; co- 




Nelfinavir (Viracept) Antiretroviral Protease inhibitor In vitro dosage: EC50 
= 1.13, EC90 = 1.76 
Upset stomach, Diarrhea HIV – Co-administration with drugs 




the IC50 of 1.3 μM 
Teicoplanin 
(Targocid) 
Antibiotic Cathepsin L 
blocker 
In vitro dosage: IC50 
= 1.66 






– Hypersensitivity to Teicoplanin 










500 mg on day 1 
followed by 250 mg 
once daily 
Stomach pain, Diarrhea, 
Nausea, Vomiting, Shortness 









azithromycin. History of 
cholestatic jaundice/hepatic 
dysfunction associated with 




Chloroquine (Aralen) Antimalarial Lysosome 
inhibitor 
600 mg base once on 
day 1 followed by 
300 mg base once 
Nausea, Vomiting, Diarrhea, 
Headache, Hair loss, 




chloroquine, the presence of 
retinal or visual field changes of 
Ineffective and 
clinical trials 
(continued on next page) 
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Table 1 (continued ) 
Agent Classification Target Treatment Dosage Common side effects Approved for Clinical trials (Based 
on Clinicaltrials. 
gov) 
Contraindication Comments for 
COVID-19 




any etiology (when used for 
indications other than acute 
malaria) 
paused by FDA on 





800 mg once on day 
1, followed by 400 
mg/day as a single 
dose or in 2 divided 
doses 
Headache, Dizziness, nausea, 
vomiting, stomach pain, 
weight loss, feeling irritated, 
skin rash, hair loss 
Malaria, Rheumatoid 







Known hypersensitivity to 
HCQ, 4-aminoquinoline 
derivatives, or any component 
of the formulation. 
Ineffective and 
clinical trials 
paused by FDA on 












thalidomide or any component 





Bevacizumab Monoclonal antibody Anti-VEGF 7.5 or 15 milligrams 
per kilogram (mg/kg) 
IV. 
Dry mouth, 
Cough, Voice changes, loss of 




Hypersensitivity in severe 
cardiac disease, Thrombosis, 
Hemorrhage, Stroke, 






Monoclonal antibody Interleukin 
inhibitor 
8 mg/kg, Maximum 
(800 mg/dose) 
Headache, Dizziness, Upper 
abdominal pain, Mouth 
ulcers, Neutropenia, 
Thrombocytopenia, increased 
liver enzymes, increased total 









Known hypersensitivity to 
Tocilizumab or any component 
of the formulation 
Contradictory 
results 




Neutropenia, increased ALT, 
injection site redness, 








Active tuberculosis, inactive 
tuberculosis, 
opportunistic fungal infection 







2 mg/kg/day (Max: 
100 mg/day) or 4 
mg/kg/day (Max: 
200 mg/day) 
Redness, Swelling, Bruising, 
or pain at the site of injection 
Rheumatoid arthritis (NCT03265132) 
(NCT04443881) 
(NCT03002974) 
E. coli protein hypersensitivity 
or hypersensitivity to Anakinra 
or any components of the 
product. 
Effective compared 
to standard care 




the viral load 
reduction 
The EC50 for IFN-α 
and IFN-β in vitro: 
1.35 IU/ml and 0.76 
IU/ml, respectively. 
INF-α: Cardiac arrhythmias, 
Anorexia, Seizures, 
Retinopathy, Numbness, 
Palpitation, Paresthesia, and 
Dizziness. 




















Seizures, Coronary artery 
disease, Autoimmune hepatitis. 
INF-β: Depression, Lactation. 
INF-λ: Hypersensitivity. 
Significant 









15 mg/kg Dry cough, Cramps, 
Pain in legs or back, 
Stomach pain, Diarrhea, 
Headache, Dizziness; 






Hypersensitivity to losartan or 












Fluid retention or Swelling of 
feet and legs, High blood 






Hypersensitivity to active 
ingredient or any component of 
Can be used in 
specific clinical 
conditions. 
(continued on next page) 
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Table 1 (continued ) 
Agent Classification Target Treatment Dosage Common side effects Approved for Clinical trials (Based 
on Clinicaltrials. 
gov) 
Contraindication Comments for 
COVID-19 
Or Equivalent total 
daily doses of 
alternative 
glucocorticoids 











Anthelmintic IMP α/β1- 
mediated nuclear 
import inhibitor 
600 μg/kg once daily Headache, Muscle aches; 
Dizziness; 
Nausea, Diarrhea; 
Mild skin rash 
Parasitic infections (NCT04381884) 
(NCT04360356) 
(NCT04405843) 
Hypersensitivity to Ivermectin 
or any component of the 
formulation 
Effective in in vitro 
examinations and 
safe. 




500 mg every 6 h for 
14 days 
Nausea, Stomach pain; 
Headache, 
Discolored urine 






Hypersensitivity in hepatic or 
renal impairment, Diabetes, 




coronaviruses in in 
vitro 
Emetine Antiprotozoal Protein synthesis 
inhibitor: binds to 
ribosomal E site 
In vitro dosage: EC50 
= 0.46 μM 
Myositis at the injection site, 
hypotension, tachycardia, 




Amoebiasis – Contraindicated in renal, 
cardiac, and muscular disease 
and is used cautiously in 
children and elderly patients 
Effective in in vitro 
with EC50 at 0.46 
μM 
Famotidin Anti-acid H2 antagonist 40 mg–60 mg 8hourly Constipation, diarrhea, 
fatigue, dizziness, weakness, 











An empty stomach 
along with other 
treatments 
Heparin (LMWH) Anticoagulant Anti-thrombin UFH 250 U/kg or 
LMWH 100 U/kg 
twice daily 
Bruising, Bleeding, Irritation, 
Pain, Redness 
Prophylaxis 








Hypersensitivity, past or 
present heparin-induced 





AbbreviationsHIV: human immunodeficiency virus; CYP3A: Cytochrome P4503A; RdRp: RNA-dependent RNA-polymerase; RBC: red blood cell; IV: intravenous; FDA: food drug administration; g: gram; mg: milligram; kg: 
kilogram; DW: dextrose water; EC50: half maximal effective concentration; IC50: half maximal inhibitory concentration; HCQ: hydroxychloroquine; TNF-α; tumor necrosis factor: VEGF: vascular Endothelial Growth 
Factor; IL-6: Interleukin-6; ALT: alanine aminotransferase; INF-α: interferon-α; INF-β: interferon- β; INF-λ: interferon- λ; IU: international unit; IL-1: Interleukin-6; IMPα/β1: importin α/β1; U: unit; UFH: unfractionated 
heparin; LMWH: low molecular weight heparin. 




Physical and chemical information and structure of drugs 
(https://www.usp.org/); (https://pubchem.ncbi.nlm.nih.gov/).  








Solubility Identification IUPAC Name Structure 
1 Darunavir C27H37N3O7S 74–76 547.7 White, 
amorphous 
solid 
Solid In water 
0.15 mg/ml 
at 20 ◦C 
HPLC [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro [2,3-b]furan-4-yl] N-[(2S,3R)- 
4-[(4-aminophenyl) sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1- 
phenylbutan-2-yl]carbamate 
2 Oseltamivir C16H28N2O4 190–206 312.4 White, solid Solid In water, 
1.6 × 10 +
3 mg/L at 
25 ◦C 
LC ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1- 
carboxylate 








4 Umifenovir C22H25BrN2O3S 133–137 477.4 White, Solid Solid “Expected to 
be poorly 
soluble 
HPLC ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2- 
[(phenylsulfanyl)methyl]-1H-indole-3-carboxylate 








HPLC Mass/Mass 2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4] 
triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy- 
phenoxyphosphoryl]amino]propanoate 
6 Ribavirin C8H12N4O5 174–176 244.2 Colorless, 
Solid 
Solid In water, 
142 mg/ml 
at 25 ◦C 
IR, TLC 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4- 
triazole-3-carboxamide 
7 Nafamostat C19H17N5O2 217–220◦ 347.4 Colorless, 
Solid 
Solid In water, 25 
mg/ml at 
25 ◦C 
HLPC (6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino) 
benzoate 











Camostat C20H22N4O5 194–198 398.4 white to 
tan, Solid 
Solid In water, 24 
mg/ml at 
25 ◦C 
HPLC [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4- 
(diaminomethylideneamino)benzoate 




















(continued on next page) 
P. Tarighi et al.                                                                                                                                                                                                                                  
EuropeanJournalofPharmacology895(2021)173890
16
Table 2 (continued ) 








Solubility Identification IUPAC Name Structure 










12 Teicoplanin C88H97Cl2N9O33 260 1879.7 white to 
faint yellow 












13 Azithromycin C38H72N2O12 126 749 Amorphous 
solid 
Solid In water, 
2.37 mg/ml 
at 25 ◦C 




14 Hydroxychloroquine C18H26ClN3O 89–91 335.9 white Solid In 
water,2.61e- 
02 g/L at 
25 ◦C 
LC 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol 
15 Thalidomide C13H10N2O4 270 258.23 Needles Solid In water, 
545 mg/L at 
25 ◦C 
HPLC, TLC 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione 
16 Losartan C22H23ClN6O 178–184 422.9 Light 
yellow solid 
Solid In water, 
8.22 mg/L 
at 25 ◦C 
HPLC [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl] 
imidazol-4-yl]methanol 










18 Ivermectin C48H74O14 155 875.1 colorless, 
Solid 
Solid In water, 4 
mg/L at 
25 ◦C 






19 Nitazoxanide C12H9N3O5S 202 307.28 Solid HPLC 2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl acetate (continued on next page) 
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infection and avoid the burden of any upcoming outbreak. 
Regarding preliminary reports in clinical practices, the combined 
usage of potential antiviral drugs with a different mechanism of action 
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Perner, A., Petersen, W.M., Savović, J., Tomazini, B., Veiga, V.C., Webb, S., 
Marshall, J.C., 2020. Association between administration of systemic corticosteroids 
and mortality among critically ill patients with COVID-19 A meta-analysis. J. Am. 
Med. Assoc. 324 (13), 1330–1341. https://doi.org/10.1001/jama.2020.17023. 
Taiub, A., Chowdhury, M.M., Shahbaz, M., Karim, R., Islam, J., Guo, D., 2020. 
A Randomized Trial of Ivermectin-doxycycline and Hydroxychloroquine- 
azithromycin Therapy on COVID19 Patients. Research Square. https://doi.org/ 
10.21203/rs.3.rs-38896/v1. 
Tanaka, T., Narazaki, M., Kishimoto, T., 2014. IL-6 en la inflamación, la inmunidad, y la 
enfermedad. Cold Spring Harb Perspect Biol 6, a016295. https://doi.org/10.1101/ 
cshperspect.a016295. 
Te, H.S., Randall, G., Jensen, D.M., 2007. Mechanism of action of ribavirin in the 
treatment of chronic hepatitis C. J. Gastroenterol. Hepatol. 3 (3), 218–225. PMID: 
21960835.  
The efficacy and safety of thalidomide combined with low-dose hormones in the 
treatment of severe Covid-19. https://clinicaltrials.gov/ct2/show/NCT04273581? 
term=NCT04273581&draw=2&rank=1. 
The efficacy and safety of thalidomide in the adjuvant treatment of moderate new 
coronavirus (Covid-19) pneumonia. https://clinicaltrials.gov/ct2/show/NCT04273 
529?term=NCT04273529&draw=2&rank=1.. 
To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients 
hospitalized with severe or critical COVID-19. https://clinicaltrials.gov/ct2/show/ 
NCT04327388.. 
Tocilizumab in COVID-19 pneumonia (TOCIVID-19) (TOCIVID-19). https://clinicaltrials. 
gov/ct2/show/NCT04317092.. 
Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis. https://clinicaltrials.gov/c 
t2/show/NCT04315480. 
Tolouian, R., Vahed, S.Z., Ghiyasvand, S., Tolouian, A., Ardalan, M., 2020. COVID-19 
interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; 
looking at a potential treatment. J. Ren. Inj. Prev. 9, e19. https://doi.org/10.34172/ 
jrip.2020.19. 
Tong, S., Su, Y., Yu, Y., Wu, C., Chen, J., Wang, S., Jiang, J., 2020. Ribavirin therapy for 
severe COVID-19: a retrospective cohort study. Int. J. Antimicrob. Agents 56 (3), 
106114. https://doi.org/10.1016/j.ijantimicag.2020.106114. 
Tu, Y.-F., Chien, C.-S., Yarmishyn, A.A., Lin, Y.-Y., Luo, Y.-H., Lin, Y.-T., Lai, W.-Y., 
Yang, D.-M., Chou, S.-J., Yang, Y.-P., 2020. A review of SARS-CoV-2 and the ongoing 
clinical trials. J. Med. Virol. 21, 2657. https://doi.org/10.3390/ijms21072657. 
usphttps://www.usp.org/. 
Uzunova, K., Filipova, E., Pavlova, V., Vekov, T., 2020. Insights into antiviral 
mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine 
affecting the new SARS-CoV-2. Biomed. Pharmacother. https://doi.org/10.1016/j. 
biopha.2020.110668, 110668.  
Van de Veerdonk, F., Netea, M.G., van Deuren, M., van der Meer, J.W., de Mast, Q., 
Bruggemann, R.J., van der Hoeven, H., 2020. Kinins and Cytokines in COVID-19: a 
Comprehensive Pathophysiological Approach. https://doi.org/10.20944/ 
preprints202004.0023.v1. Preprints. 2020040023.  
Vincent, M.J., Bergeron, E., Benjannet, S., Erickson, B.R., Rollin, P.E., Ksiazek, T.G., 
Seidah, N.G., Nichol, S.T., 2005. Chloroquine is a potent inhibitor of SARS 
coronavirus infection and spread. Virol. J. 2, 69. https://doi.org/10.1186/1743- 
422X-2-69. 
Walls, A.C., Park, Y.-J., Tortorici, M.A., Wall, A., McGuire, A.T., Veesler, D., 2020. 
Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 
281–292. https://doi.org/10.1016/j.cell.2020.02.058. 
Wang, Y., Fei, D., Vanderlaan, M., Song, A., 2004. Biological activity of bevacizumab, a 
humanized anti-VEGF antibody in vitro. Angiogenesis 7, 335–345. https://doi.org/ 
10.1007/s10456-004-8272-2. 
Wang, Y., Zhang, D., Du, G., Du, R., Jianping Zhao, J., Jin, Y., Shouzhi Fu, S., Gao, L., 
Zhenshun Cheng, Z., Lu, Q., Hu, Y., Guangwei Luo, G., Wang, K., Lu, Y., Li, H., 
Wang, S., Ruan, S., Yang, C., Mei, C., Wang, Yi, Ding, D., Wu, F., Tang, X., Ye, X., 
Ye, Y., Liu, B., Yang, J., Yin, W., Wang, A., Fan, G., Zhou, F., Liu, Z., Gu, X., Xu, J., 
Shang, L., Zhang, Y., Cao, L., Guo, T., Wan, Y., Qin, H., Jiang, Y., Jaki, T., Hayden, F. 
G., Horby, P.W., Bin Cao, B., Wang, C., 2020. Remdesivir in adults with severe 
COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 
395, 1569–1578. https://doi.org/10.1016/S0140-6736(20)31022-31029. 
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., 
Xiong, Y., 2020a. Clinical characteristics of 138 hospitalized patients with 2019 
novel coronavirus–infected pneumonia in Wuhan, China. Jama 323, 1061–1069. 
https://doi.org/10.1001/jama.2020.1585. 
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., Xiao, G., 
2020b. Remdesivir and chloroquine effectively inhibit the recently emerged novel 
coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269–271. https://doi.org/10.1038/ 
s41422-020-0282-0. 
Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., Lu, G., Qiao, C., Hu, Y., 
Yuen, K.-Y., 2020c. Structural and functional basis of SARS-CoV-2 entry by using 
human ACE2. Cell 181, 894–904. https://doi.org/10.1016/j.cell.2020.03.045. 
Wang, Y., Jiang, W., He, Q., Wang, C., Wang, B., Zhou, P., Dong, N., Tong, Q., 2020d. 
Early, Low-dose and Short-term Application of Corticosteroid Treatment in Patients 
with Severe COVID-19 Pneumonia: single-Center Experience from Wuhan, China. 
https://doi.org/10.1101/2020.03.06.20032342. MedRxiv.  
Ward, P., Small, I., Smith, J., Suter, P., Dutkowski, R., 2005. Oseltamivir (Tamiflu®) and 
its potential for use in the event of an influenza pandemic. J. Antimicrob. 
Chemother. 55, i5–i21. https://doi.org/10.1093/jac/dki018. 
Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., Wang, Q., Xu, Y., Li, M., Li, X., 
2020a. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential 
drugs by computational methods. Acta Pharm. Sin. B 10, 766–788. https://doi.org/ 
10.1016/j.apsb.2020.02.008. 
Wu, J., Liu, J., Zhao, X., Liu, C., Wang, W., Wang, D., Xu, W., Zhang, C., Yu, J., Jiang, B., 
2020b. Clinical characteristics of imported cases of COVID-19 in jiangsu province: a 
multicenter descriptive study. Clin. Infect. Dis. 71, 706–712. https://doi.org/ 
10.1093/cid/ciaa199. 
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., 
2020a. Effective treatment of severe COVID-19 patients with tocilizumab. Pnas 17, 
202003. https://doi.org/10.1073/pnas.2005615117 v1.  
Xu, Z., Peng, C., Shi, Y., Zhu, Z., Mu, K., Wang, X., Zhu, W., 2020b. Nelfinavir was 
Predicted to be a Potential Inhibitor of 2019-nCov Main Protease by an Integrative 
Approach combining Homology Modelling, Molecular Docking and Binding Free 
Energy Calculation. BioRxiv. https://doi.org/10.1101/2020.01.27.921627. 
Yamamoto, N., Yang, R., Yoshinaka, Y., Amari, S., Nakano, T., Cinatl, J., Rabenau, H., 
Doerr, H.W., Hunsmann, G., Otaka, A., 2004. HIV protease inhibitor nelfinavir 
inhibits replication of SARS-associated coronavirus. Biochem. Biophys. Res. 
Commun. 318, 719–725. https://doi.org/10.1016/j.bbrc.2004.04.083. 
Yamamoto, N., Matsuyama, S., Hoshino, T., Yamamoto, N., 2020. Nelfinavir Inhibits 
Replication of Severe Acute Respiratory Syndrome Coronavirus 2 in vitro. BioRxiv. 
https://doi.org/10.1101/2020.04.06.026476. 
Yao, T.T., Qian, J.D., Zhu, W.Y., Wang, Y., Wang, G.Q., 2020a. A systematic review of 
lopinavir therapy for SARS coronavirus and MERS coronavirus—a possible reference 
for coronavirus disease-19 treatment option. J Med. Virol. 92, 556–563. https://doi. 
org/10.1002/jmv.25729. 
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., 
2020b. In vitro antiviral activity and projection of optimized dosing design of 
hydroxychloroquine for the treatment of severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 71, 732–739. https://doi.org/ 
10.1093/cid/ciaa237. 
Young, B., Tan, T.T., Leo, Y.S., 2020. The place for remdesivir in COVID-19 treatment. 
Lancet Infect. Dis. 21 https://doi.org/10.1016/S1473-3099(20)30911-7. 
Zeinalian, M., Salari-Jazi, A., Jannesari, A., Khanahmad, H., 2020. A potential protective 
role of losartan against coronavirus-induced lung damage. Infect. Control Hosp. 
Epidemiol. 41, 752–753. https://doi.org/10.1017/ice.2020.80. 
Zha, L., Li, S., Pan, L., Tefsen, B., Li, Y., French, N., Chen, L., Yang, G., Villanueva, E.V., 
2020. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID- 
19). Med. J. Aust. 212 (9) https://doi.org/10.5694/mja2.50577. Preprint.  
Zhang, L., Zhou, R., 2020. Binding Mechanism of Remdesivir to SARS-CoV-2 RNA 
Dependent RNA Polymerase. https://doi.org/10.20944/preprints202003.0267.v1. 
Preprints. 2020030267.  
Zhang, C., Wu, Z., Li, J.-W., Zhao, H., Wang, G.-Q., 2020a. The cytokine release 
syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist 
Tocilizumab may be the key to reduce the mortality. Int. J. Antimicrob. Agents 55, 
105954. https://doi.org/10.1016/j.ijantimicag.2020.105954. 
Zhang, J., Ma, X., Yu, F., Liu, J., Zou, F., Pan, T., Zhang, H., 2020b. Teicoplanin Potently 
Blocks the Cell Entry of 2019-nCoV. https://doi.org/10.1101/2020.02.05.935387. 
BioRxiv.  
Zhang, X., Song, K., Tong, F., Fei, M., Guo, H., Lu, Z., Wang, J., Zheng, C., 2020c. First 
case of COVID-19 in a patient with multiple myeloma successfully treated with 
tocilizumab. Blood Adv. 4, 1307. https://doi.org/10.1182/ 
bloodadvances.2020001907. 
Zhou, Y.-H., Qin, Y.-Y., Lu, Y.-Q., Sun, F., Yang, S., Harypursat, V., Tang, S.-Q., 
Huang, Y.-Q., He, X.-Q., Zeng, Y.-M., 2020a. Effectiveness of glucocorticoid therapy 
in patients with severe novel coronavirus pneumonia: protocol of a randomized 
controlled trial. Chin Med J (Engl). 133, 1080–1086. https://doi.org/10.1097/ 
CM9.0000000000000791. 
Zhou, Q., Chen, V., Shannon, C.P., Wei, X.-S., Xiang, X., Wang, X., Wang, Z.-H., 
Tebbutt, S.J., Kollmann, T.R., Fish, E.N., 2020b. Interferon-a2b treatment for 
COVID-19. Front. Immunol. 11, 1061. https://doi.org/10.3389/fimmu.2020.01061. 
P. Tarighi et al.                                                                                                                                                                                                                                  
